EGFR and non-small cell lung carcinoma: Evidence from other studies showed that CXB–erlotinib combination or CXB alone treatment can enhance radiosensitivity in A549 lung cells (40) and may be beneficial for patients with advanced NSCLC and EGFR wild type only (41).